FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2955478352> ?p ?o ?g. }

• W2955478352 endingPage "2696" @default.
• W2955478352 startingPage "2696" @default.
• W2955478352 abstract "Abstract E3 ubiquitin ligases play critical roles in directing cellular protein fate by controlling the specificity of ubiquitin conjugation to substrate proteins and targeting them for cellular relocalization or degradation by the ubiquitin proteasome system. The E3 ubiquitin ligase CBL-B is expressed in immune cell lineages and negatively regulates activity of the T-cell receptor (TCR) by imposing a requirement for a costimulatory signal to mount a productive immune response upon TCR engagement. Mice deficient in Cbl-b, and more specifically in the RING Zn-finger ligase domain of Cbl-b, demonstrate a tumor rejection phenotype mediated by CD8+ T cells (Paolino et al., JI, 2011). We have reproduced these results and demonstrate that Cbl-b deficient mice show enhanced anti-tumor activity. In addition, we show that CD4+ and CD8+ T cells from mice deficient in Cbl-b have 5 to 10-fold enhanced secretion of IL-2 and IFN γ when stimulated ex vivo. These data provide a genetic rationale for the development of a small molecule inhibitor of CBL-B ligase activity for use in patients with tumor-mediated immune suppression of effector T cells. We have identified a series of small molecule inhibitors of CBL-B activity with biochemical potency at low nanomolar concentrations. CBL-B inhibitors increased cytokine secretion in vitro at low nanomolar concentrations, as measured by IL-2 and IFN γ secretion, in primary human and mouse T cells stimulated with CD3/CD28 or CD3 alone. The compounds also stimulated proliferation and elevated levels of the T cell surface activation markers CD25 and CD69. CBL-B inhibitors enhanced an antigen recall response in human PBMCs ex vivo, as measured by approximately 5-fold higher secretion of GM-CSF, TNF-α and RANTES, and demonstrated effects in an ex vivo model of exhausted T cell function. Oral dosing of an optimized CBL-B inhibitor enhanced anti-CD3 stimulated T cell activation in mouse CD4+ and CD8+ T cells, demonstrating a dose proportional pharmacodynamic effect. Oral administration over 28 days in the syngeneic CT-26 tumor model was well tolerated and resulted in single agent tumor growth inhibition. These data support the continued advancement of small molecule oral CBL-B inhibitors for future development in immuno-oncology. Citation Format: Jennifa Gosling, Ryan Rountree, Asad Taherbhoy, Chenbo Wang, Thomas Cummins, Frederick Cohen, Hiroko Tanaka, Dahlia Weiss, Mario Cardozo, Christopher Karim, May Tan, Joseph Juan, Austin Tenn-McClellan, Szerenke Kiss von Soly, Julie Sheung, Kathleen Boyle, Ketki Dhamnaskar, Katherine Kurylo, Jilliane Bruffey, Jennifer McKinnell, Dane Karr, Andria Christianson, Anne-Renee Van Der Vuurst de Vries, Pallavur Sivakumar, Mark Gallop, Paul A. Barsanti, Anjanabha Saha, Neil F. Bence, Christoph W. Zapf. Genetic and pharmacologic evaluation of the ubiquitin ligase CBL-B as a small-molecule, tumor immunotherapy target [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2019; 2019 Mar 29-Apr 3; Atlanta, GA. Philadelphia (PA): AACR; Cancer Res 2019;79(13 Suppl):Abstract nr 2696." @default.
• W2955478352 created "2019-07-12" @default.
• W2955478352 creator A5005426681 @default.
• W2955478352 creator A5006674728 @default.
• W2955478352 creator A5011506026 @default.
• W2955478352 creator A5012929939 @default.
• W2955478352 creator A5014840827 @default.
• W2955478352 creator A5014928176 @default.
• W2955478352 creator A5019964160 @default.
• W2955478352 creator A5025011775 @default.
• W2955478352 creator A5029857666 @default.
• W2955478352 creator A5035665075 @default.
• W2955478352 creator A5036075683 @default.
• W2955478352 creator A5037530058 @default.
• W2955478352 creator A5039394135 @default.
• W2955478352 creator A5047128610 @default.
• W2955478352 creator A5047867041 @default.
• W2955478352 creator A5048152167 @default.
• W2955478352 creator A5048852631 @default.
• W2955478352 creator A5052411449 @default.
• W2955478352 creator A5057936922 @default.
• W2955478352 creator A5066673243 @default.
• W2955478352 creator A5068982383 @default.
• W2955478352 creator A5080450210 @default.
• W2955478352 creator A5080764781 @default.
• W2955478352 creator A5082774803 @default.
• W2955478352 creator A5086221395 @default.
• W2955478352 creator A5088611614 @default.
• W2955478352 creator A5089156905 @default.
• W2955478352 creator A5089636566 @default.
• W2955478352 creator A5091076202 @default.
• W2955478352 date "2019-07-01" @default.
• W2955478352 modified "2023-09-23" @default.
• W2955478352 title "Abstract 2696: Genetic and pharmacologic evaluation of the ubiquitin ligase CBL-B as a small-molecule, tumor immunotherapy target" @default.
• W2955478352 doi "https://doi.org/10.1158/1538-7445.am2019-2696" @default.
• W2955478352 hasPublicationYear "2019" @default.
• W2955478352 type Work @default.
• W2955478352 sameAs 2955478352 @default.
• W2955478352 citedByCount "1" @default.
• W2955478352 countsByYear W29554783522021 @default.
• W2955478352 crossrefType "journal-article" @default.
• W2955478352 hasAuthorship W2955478352A5005426681 @default.
• W2955478352 hasAuthorship W2955478352A5006674728 @default.
• W2955478352 hasAuthorship W2955478352A5011506026 @default.
• W2955478352 hasAuthorship W2955478352A5012929939 @default.
• W2955478352 hasAuthorship W2955478352A5014840827 @default.
• W2955478352 hasAuthorship W2955478352A5014928176 @default.
• W2955478352 hasAuthorship W2955478352A5019964160 @default.
• W2955478352 hasAuthorship W2955478352A5025011775 @default.
• W2955478352 hasAuthorship W2955478352A5029857666 @default.
• W2955478352 hasAuthorship W2955478352A5035665075 @default.
• W2955478352 hasAuthorship W2955478352A5036075683 @default.
• W2955478352 hasAuthorship W2955478352A5037530058 @default.
• W2955478352 hasAuthorship W2955478352A5039394135 @default.
• W2955478352 hasAuthorship W2955478352A5047128610 @default.
• W2955478352 hasAuthorship W2955478352A5047867041 @default.
• W2955478352 hasAuthorship W2955478352A5048152167 @default.
• W2955478352 hasAuthorship W2955478352A5048852631 @default.
• W2955478352 hasAuthorship W2955478352A5052411449 @default.
• W2955478352 hasAuthorship W2955478352A5057936922 @default.
• W2955478352 hasAuthorship W2955478352A5066673243 @default.
• W2955478352 hasAuthorship W2955478352A5068982383 @default.
• W2955478352 hasAuthorship W2955478352A5080450210 @default.
• W2955478352 hasAuthorship W2955478352A5080764781 @default.
• W2955478352 hasAuthorship W2955478352A5082774803 @default.
• W2955478352 hasAuthorship W2955478352A5086221395 @default.
• W2955478352 hasAuthorship W2955478352A5088611614 @default.
• W2955478352 hasAuthorship W2955478352A5089156905 @default.
• W2955478352 hasAuthorship W2955478352A5089636566 @default.
• W2955478352 hasAuthorship W2955478352A5091076202 @default.
• W2955478352 hasConcept C104317684 @default.
• W2955478352 hasConcept C134459356 @default.
• W2955478352 hasConcept C148125776 @default.
• W2955478352 hasConcept C153911025 @default.
• W2955478352 hasConcept C154317977 @default.
• W2955478352 hasConcept C167672396 @default.
• W2955478352 hasConcept C185592680 @default.
• W2955478352 hasConcept C19317047 @default.
• W2955478352 hasConcept C202751555 @default.
• W2955478352 hasConcept C203014093 @default.
• W2955478352 hasConcept C25602115 @default.
• W2955478352 hasConcept C27740335 @default.
• W2955478352 hasConcept C2776090121 @default.
• W2955478352 hasConcept C502942594 @default.
• W2955478352 hasConcept C55493867 @default.
• W2955478352 hasConcept C86803240 @default.
• W2955478352 hasConcept C8891405 @default.
• W2955478352 hasConcept C95444343 @default.
• W2955478352 hasConceptScore W2955478352C104317684 @default.
• W2955478352 hasConceptScore W2955478352C134459356 @default.
• W2955478352 hasConceptScore W2955478352C148125776 @default.
• W2955478352 hasConceptScore W2955478352C153911025 @default.
• W2955478352 hasConceptScore W2955478352C154317977 @default.
• W2955478352 hasConceptScore W2955478352C167672396 @default.
• W2955478352 hasConceptScore W2955478352C185592680 @default.
• W2955478352 hasConceptScore W2955478352C19317047 @default.
• W2955478352 hasConceptScore W2955478352C202751555 @default.
• W2955478352 hasConceptScore W2955478352C203014093 @default.

• next